Immunecheckpointinhibitors相关论文
目的:探讨F框/WD-40域蛋白7（FBXW7）基因突变对非小细胞肺癌（NSCLC）患者免疫治疗预后的影响。方法:（1）选取2019年1月至2021年6月南京医科......
免疫检查点抑制剂（ICI）在过去十年迅速发展，并成为最具有前景的肿瘤治疗之一。但ICI打破了机体的免疫平衡，降低了T细胞耐受性，导致机体......
免疫检查点抑制剂(ICIs)在国内外临床试验的多种恶性肿瘤治疗中表现出了显著的疗效，在我国已被批准进入临床应用。ICIs治疗引起的免......
目的:在原发性肝癌患者中评估以免疫检查点抑制剂为基础的联合治疗引起的肝功能损伤发生情况。方法:回顾性分析2018年1月1日至2021......
免疫检查点抑制剂（ICIs）的临床应用显著改善肝细胞癌（简称肝癌）病人预后。随着ICIs在肝癌中的广泛应用，免疫相关不良反应（irAE）越来越受到......
Peripheral CD4+T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chin
Limited benefit population of immune checkpoint inhibitors makes it urgent to screen predictive biomarkers for stratifyi......
High Incidence of Venous Thromboembolism Due to Immune Checkpoint Inhibitors:an Immunotherapy-relate
The incidence of venous thromboembolism(VTE)in cancer patients is 4-7 times higher than that in the general population.V......
Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance i
...
...
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse ev
Objective: We aimed to retrospectively analyze the toxicity profiles and predictors of immune-related adverse events (ir......
近年来，随着免疫检查点抑制剂(ICIs)的开发应用，免疫治疗在肿瘤领域所发挥的作用越来越受到广泛关注，其在多种肿瘤中取得的良好效果也......
肝细胞癌(HCC)是我国常见的恶性肿瘤。目前，肝切除仍是早期HCC的主要治疗手段，但能获得根治性切除的病例不足20%，超80%患者确诊时已是......
尿路上皮癌是常见的泌尿系恶性肿瘤。含铂化疗方案作为局部晚期或转移性尿路上皮癌的标准一线治疗虽有效，但部分患者无法耐受，且存在......
...
Hepatocellular carcinoma (HCC) is a poor prognosis tumor when not accessible to potentially curative treatments such as ......
Hepatocellular carcinoma (HCC) accounts for 75％-85％ of all primary liver cancers and is the leading cause of cancer-relate......
